Sweden’s Gesynta ‘Phase IIa Ready’ After Private Placing
Lead Asset Aims To Treat Chronic Inflammation In Systemic Sclerosis
Executive Summary
Gesynta’s SEK190m ($20m) private placement allows its lead asset to enter Phase IIa studies for treating chronic inflammatory conditions in certain systemic sclerosis patients.